ClinicalTrials.Veeva

Menu

Cryotherapy & Oxaliplatin

NYU Langone Health logo

NYU Langone Health

Status

Not yet enrolling

Conditions

Peripheral Neuropathy
Colon Cancer

Treatments

Device: Cryotherapy Gloves

Study type

Interventional

Funder types

Other

Identifiers

NCT06281925
22-01363

Details and patient eligibility

About

The primary objective of this study is to determine if cryotherapy is beneficial to patients with colon cancer who are receiving oxaliplatin in the prevention of developing chemotherapy induced peripheral neuropathy.

Full description

Peripheral neuropathy often manifests as numbness and tingling in the hands and feet, which may be detrimental to the patients' overall safety and quality of life, thereby causing them to stop or delay treatment. Everyday tasks such as walking, buttoning a shirt, or tying shoes can become challenging. Select chemotherapy agents are known to cause significant peripheral neuropathy. Studies have been performed demonstrating efficacy of using cryotherapy, which causes vasoconstriction, to targeted areas of the body, in relation to paclitaxel. These studies have shown drastic differences between those who receive cryotherapy during treatment and those who do not. There are few studies on the use of cryotherapy in the prevention of peripheral neuropathy with the use of oxaliplatin, which will be undertaken in this study.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Over the age of 18 years
  • Willingness to participate in research
  • Diagnosed with stage III colon cancer
  • Chemotherapy naïve
  • Planning to initiate Capecitabine + Oxaliplatin (CAPOX) chemotherapy regimen as part of standard of care.

Exclusion criteria

  • Pre-existing peripheral neuropathy
  • Pre-existing diabetes
  • Raynaud's disease
  • Metabolic syndrome, including: Hypertension; Hypercholesterolemia; and Obesity (BSA > 2)
  • Upper extremity amputees
  • Specific autoimmune diseases: Guillain-Barre; Lupus; Rheumatoid arthritis; and Sjogren's syndrome

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

40 participants in 2 patient groups

Cryotherapy
Experimental group
Description:
Patients receiving oxaliplatin who are randomized to the Interventional (Cryotherapy) Arm will wear a pair of gloves that has removable ice packs throughout their treatment, starting 15 minutes before and ending 15 minutes after completion of oxaliplatin. These ice packs will be replaced every 30 minutes. The total wearing time of the cryotherapy will be approximately 2 hours.
Treatment:
Device: Cryotherapy Gloves
Control
No Intervention group
Description:
Patients receiving oxaliplatin who are randomized to the Control Arm will not receive the gloves with removable ice packs throughout their treatment.

Trial contacts and locations

2

Loading...

Central trial contact

Sarah Mendez

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems